HY-112038-25mg
|
MedChemexpress LLC
|
GSK2983559 (free acid) [CAS 1579965-12-0]
|
|
COVID-19-immunoregulation
|
|
HY-112038-5mg
|
MedChemexpress LLC
|
GSK2983559 (free acid) [CAS 1579965-12-0]
|
|
COVID-19-immunoregulation
|
|
HY-112038-50mg
|
MedChemexpress LLC
|
GSK2983559 (free acid) [CAS 1579965-12-0]
|
|
COVID-19-immunoregulation
|
|
HY-12501-10mg
|
MedChemexpress LLC
|
ITI-214 (free base) [CAS 1160521-50-5]
|
|
Neuroscience-Neuromodulation
|
|
HY-12501-5mg
|
MedChemexpress LLC
|
ITI-214 (free base) [CAS 1160521-50-5]
|
|
Neuroscience-Neuromodulation
|
|
HY-12501-50mg
|
MedChemexpress LLC
|
ITI-214 (free base) [CAS 1160521-50-5]
|
|
Neuroscience-Neuromodulation
|
|
HY-17638-10mg
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-17638-100mg
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-17638-25mg
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-17638-5mg
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-17638-50mg
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-17638-1mL
|
MedChemexpress LLC
|
Mizagliflozin [CAS 666843-10-3] (10mM in DMSO)
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-P76498-100ug
|
MedChemexpress LLC
|
MMP-26, Human
|
|
|
|
HY-P76498-20ug
|
MedChemexpress LLC
|
MMP-26, Human
|
|
|
|